Tuying Yong

Nov 4, 2024 | nature.com | Jingjie Liu |Tuying Yong |Ben Zhao |Shenghong Ju |Gao-Jun Teng |Xiangliang Yang

AbstractNerve–cancer crosstalk has gained substantial attention owing to its impact on tumour growth, metastasis and therapy resistance. Effective therapeutic strategies targeting tumour-associated nerves within the intricate tumour microenvironment remain a major challenge in pancreatic cancer.

Oct 24, 2023 | nature.com | Tuying Yong |Lu Gan

AbstractImmune checkpoint blockade (ICB) therapy, particularly antibodies targeting the programmed death receptor 1 (PD-1) and its ligand (PD-L1), has revolutionized cancer treatment. However, its efficacy as a standalone therapy remains limited. Although ICB therapy in combination with chemotherapy shows promising therapeutic responses, the challenge lies in amplifying chemotherapy-induced antitumor immunity effectively.

Sep 13, 2023 | nature.com | Tuying Yong |Xiaoping Chen |Xiangliang Yang

AbstractThe durable response rate to immune checkpoint blockade such as anti-programmed cell death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly depending on an immunosuppressive microenvironment with limited number of CD8+ T cells, especially stem-like CD8+ T cells, in tumor tissues.